

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)**

Interim Condensed Consolidated Financial Statements
For the three and nine months period ended 30 September 2021

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated financial statements
For the three and nine months period ended 30 September 2021**

INDEX	PAGE
Independent auditor's review report	1
Interim condensed consolidated statement of financial position	2
Interim condensed consolidated statement of income	3
Interim condensed consolidated statement of comprehensive income	4
Interim condensed consolidated statement of changes in equity	5
Interim condensed consolidated statement of cash flows	6
Notes to the interim condensed consolidated financial statements	7 – 13



Ernst and Young & Co Public Accountants (Professional Limited Liability Company)
Paid-up capital (SR 5,500,000) (Five million and five hundred thousand Saudi Riyal)
Head Office
Al Faisaliah Office Tower, 14th Floor
King Fahad Road
P.O. Box 2732
Riyadh 11461
Kingdom of Saudi Arabia

C.R. No. 1010383821

Tel: +966 11 215 9898
+966 11 273 4740
Fax: +966 11 273 4730

ey.ksa@sa.ey.com
ey.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TO THE SHAREHOLDERS OF DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY (SAUDI JOINT STOCK COMPANY)

Introduction:

We have reviewed the accompanying interim condensed consolidated statement of financial position of Dr. Sulaiman Al Habib Medical Services Group Company ("the Company") and its subsidiaries (collectively referred to as "the Group") as at 30 September 2021, and the related interim condensed consolidated statements of income and comprehensive income for the three and nine months periods ended 30 September 2021, and the related interim condensed consolidated changes in equity and cash flows for the nine months period then ended, and a summary of significant accounting policies and other explanatory notes. Management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34") that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of Review:

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" endorsed in the Kingdom of Saudi Arabia. A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion:

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 that is endorsed in the Kingdom of Saudi Arabia.

for Ernst & Young

Rashid S. AIRashoud
Certified Public Accountant
License No. (366)



Riyadh: 18 Rabi Al-Awwal 1443H
(24 October 2021)

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of financial position
As at 30 September 2021

	Notes	30 September 2021 SR (Unaudited)	31 December 2020 SR (Audited)
Assets			
Current assets			
Cash and cash equivalents		2,494,217,127	2,339,263,767
Accounts receivable		775,749,687	844,329,440
Advances to suppliers and contractors		23,989,569	8,325,335
Prepaid expenses and other assets		197,828,628	221,531,447
Inventories		418,341,986	379,910,293
Total current assets		3,910,126,997	3,793,360,282
Non-current assets			
Investments in associates		44,185,251	39,869,789
Property and equipment	6	6,330,168,011	5,647,943,122
Total non-current assets		6,374,353,262	5,687,812,911
Total assets		10,284,480,259	9,481,173,193
Liabilities and equity			
Liabilities			
Current liabilities			
Current portion of long-term loans	8	285,009,395	330,020,751
Accounts payable		760,785,594	628,162,484
Advances from customers		32,663,881	37,334,621
Accrued expenses and other liabilities		603,505,713	555,075,323
Zakat payable		134,319,667	101,144,451
Current portion of government grant		5,274,317	3,670,596
Current portion of lease liabilities		33,995,880	38,320,170
Total current liabilities		1,855,554,447	1,693,728,396
Non-current liabilities			
Long-term loans	8	2,271,540,734	2,029,640,764
Government grant		67,224,081	74,458,835
Lease liabilities		233,611,583	232,519,658
Employees' end-of-service benefits		472,362,507	362,296,404
Total non-current liabilities		3,044,738,905	2,698,915,661
Total liabilities		4,900,293,352	4,392,644,057
Equity			
Issued and paid-up share capital		3,500,000,000	3,500,000,000
Statutory reserve		573,420,806	573,420,806
Retained earnings		1,127,732,829	838,322,887
Equity attributable to equity holders of the parent		5,201,153,635	4,911,743,693
Non-controlling interests		183,033,272	176,785,443
Total equity		5,384,186,907	5,088,529,136
Total liabilities and equity		10,284,480,259	9,481,173,193



APPROVED BY:
FAISAL AL NASSAR
 CFO



APPROVED BY:
NASSER AL HAQBANI
 CEO



APPROVED BY:
DR. SULAIMAN AL HABIB
 CHAIRMAN

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of income
For the three and nine months period ended 30 September 2021

Notes	For the three months period ended		For the nine months period ended	
	30 September 2021 SR (Unaudited)	30 September 2020 SR (Unaudited)	30 September 2021 SR (Unaudited)	30 September 2020 SR (Unaudited)
Revenue	1,836,350,038	1,623,907,510	5,282,344,562	4,170,258,722
Cost of revenue	(1,249,931,253)	(1,065,018,812)	(3,595,490,143)	(2,851,657,372)
Gross profit	586,418,785	558,888,698	1,686,854,419	1,318,601,350
Selling and marketing expenses	(63,100,027)	(104,914,237)	(163,714,290)	(180,577,330)
General and administrative expenses	(142,779,947)	(130,084,887)	(453,242,520)	(352,215,474)
Operating income	380,538,811	323,889,574	1,069,897,609	785,808,546
Share of income (loss) of associates	1,748,936	2,615,206	7,315,462	(1,811,610)
Finance costs	(9,451,229)	(10,823,748)	(28,882,166)	(37,895,797)
Other income, net	13,280,665	11,928,106	50,510,228	42,080,801
Income before zakat	386,117,183	327,609,138	1,098,841,133	788,181,940
Zakat	(35,659,828)	(30,975,289)	(99,922,278)	(72,204,040)
Income for the period	350,457,355	296,633,849	998,918,855	715,977,900
Attributable to:				
Equity holders of the Parent	348,624,327	298,794,733	993,024,138	737,647,874
Non-controlling interests	1,833,028	(2,160,884)	5,894,717	(21,669,974)
	350,457,355	296,633,849	998,918,855	715,977,900
Earnings per share:				
<i>Basic and diluted earnings per share from income for the period attributable to equity holders of the parent</i>	9			
	1.00	0.85	2.84	2.11



APPROVED BY:
FAISAL AL NASSAR
CFO



APPROVED BY:
NASSER AL HAQBANI
CEO



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of comprehensive income
For the three and nine months period ended 30 September 2021**

	For the three months period ended		For the nine months period ended	
	30 September 2021 SR (Unaudited)	30 September 2020 SR (Unaudited)	30 September 2021 SR (Unaudited)	30 September 2020 SR (Unaudited)
Income for the period	350,457,355	296,633,849	998,918,855	715,977,900
Other comprehensive income <i>Items that will not to be reclassified to profit or loss in subsequent periods:</i>				
Remeasurement gain (loss) on employees' end-of-service benefits	786,707	1,636,562	(3,261,084)	(5,651,474)
Other comprehensive Income (loss) for the period	786,707	1,636,562	(3,261,084)	(5,651,474)
Total comprehensive income for the period	351,244,062	298,270,411	995,657,771	710,326,426
Attributable to:				
Equity holders of the parent company	349,330,486	300,346,925	989,409,942	731,825,562
Non-controlling interests	1,913,576	(2,076,514)	6,247,829	(21,499,136)
	351,244,062	298,270,411	995,657,771	710,326,426



APPROVED BY:
FAISAL AL NASSAR
CFO



APPROVED BY:
NASSER AL HAQBANI
CEO



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of changes in equity
For the nine months period ended 30 September 2021

	Attributable to equity holders of the parent				Non-controlling interests SR	Total equity SR
	Issued and paid-up share capital	Statutory reserve	Retained earnings	Total		
	SR	SR	SR	SR		
As at 1 January 2021	3,500,000,000	573,420,806	838,322,887	4,911,743,693	176,785,443	5,088,529,136
Income for the period	-	-	993,024,138	993,024,138	5,894,717	998,918,855
Other comprehensive income (loss)	-	-	(3,614,196)	(3,614,196)	353,112	(3,261,084)
Total comprehensive income	-	-	989,409,942	989,409,942	6,247,829	995,657,771
Dividends (note 7)	-	-	(700,000,000)	(700,000,000)	-	(700,000,000)
As at 30 September 2021 (Unaudited)	3,500,000,000	573,420,806	1,127,732,829	5,201,153,635	183,033,272	5,384,186,907
As at 1 January 2020	3,500,000,000	467,872,574	426,004,145	4,393,876,719	196,917,053	4,590,793,772
Income (loss) for the period	-	-	737,647,874	737,647,874	(21,669,974)	715,977,900
Other comprehensive income (loss)	-	-	(5,822,312)	(5,822,312)	170,838	(5,651,474)
Total comprehensive income (loss)	-	-	731,825,562	731,825,562	(21,499,136)	710,326,426
Dividends (note 7)	-	-	(315,000,000)	(315,000,000)	-	(315,000,000)
As at 30 September 2020 (Unaudited)	3,500,000,000	467,872,574	842,829,707	4,810,702,281	175,417,917	4,986,120,198



APPROVED BY:
FAISAL AL NASSAR
 CFO



APPROVED BY:
NASSER AL HAQBANI
 CEO



APPROVED BY:
DR. SULAIMAN AL HABIB
 CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of cash flows
For nine months period ended 30 September 2021

	2021 SR (Unaudited)	2020 SR (Unaudited)
Operating activities		
Income before zakat	1,098,841,133	788,181,940
Non-cash adjustments to reconcile income before zakat to net cash flow		
Depreciation	234,373,104	238,636,187
Share of income of associates	(7,315,462)	1,811,610
Allowance for expected credit loss	97,086,081	121,247,391
Finance costs	28,882,166	37,895,797
Employees' end-of-service benefits	131,644,888	49,005,214
	<u>1,583,511,910</u>	<u>1,236,778,139</u>
Working capital adjustments:		
Accounts receivable	(28,506,328)	291,371,367
Advances to suppliers and contractors	(15,664,234)	(273,590)
Inventories	(38,431,693)	(84,853,489)
Prepaid expenses and other assets	23,731,342	(2,445,105)
Accounts payable	132,623,110	(43,682,855)
Advances from customers	(4,670,740)	1,674,616
Accrued expenses and other liabilities	48,237,050	106,529,379
Cash generated from operations	<u>1,700,830,417</u>	<u>1,505,098,462</u>
Zakat paid	(66,747,062)	(79,675,070)
Employees' end-of-service benefits paid	(24,839,869)	(22,560,768)
Net cash from operating activities	<u>1,609,243,486</u>	<u>1,402,862,624</u>
Investing activities		
Purchase of property and equipment	(888,047,466)	(417,088,172)
Short term time deposit – Murabaha	-	(600,000,000)
Dividends from associates	3,000,000	1,000,000
Net cash used in investing activities	<u>(885,047,466)</u>	<u>(1,016,088,172)</u>
Financing activities		
Proceeds from long-term loans, net	191,257,581	93,121,351
Lease liabilities paid	(31,811,415)	(36,794,759)
Finance costs paid	(28,688,826)	(39,836,254)
Dividends paid	(700,000,000)	(315,000,000)
Net cash used in financing activities	<u>(569,242,660)</u>	<u>(298,509,662)</u>
Net increase in cash and cash equivalents	154,953,360	88,264,790
Cash and cash equivalents at the beginning of the period	2,339,263,767	1,196,660,642
Cash and cash equivalents at the end of the period	<u>2,494,217,127</u>	<u>1,284,925,432</u>
Non-cash transactions:		
Recognition of right-of-use assets	42,317,362	5,680,043
Recognition of lease liabilities	42,317,362	5,680,043



APPROVED BY:
FAISAL AL NASSAR
CFO



APPROVED BY:
NASSER AL HAQBANI
CEO



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements
30 September 2021**

1. Corporate information and activities

Dr. Sulaiman Al Habib Medical Services Group Company (the “Company”) (a Saudi joint stock company) is registered in Riyadh, Kingdom of Saudi Arabia under commercial registration number 1010118330 dated 11 Jumad Thani 1414H (corresponding to 25 November 1993). The Company was listed In the Saudi Stock Exchange (Tadawul) on 22/07/1441H (corresponding to 17 March 2020), and the Company’s head-office is located at Olaya District, King Fahad Road, P.O. Box 301578, Riyadh 11372, KSA .

The activities of the company and its following subsidiaries (collectively referred to as “the Group”), are to provide private health services and ancillary services for its operations in the Kingdom and the region through the establishment, management and operation of hospitals, general and specialized medical complexes, day surgery centers, pharmaceutical facilities, and other ancillary areas, which include providing services. Home medical care, specialized medical laboratories, technology services, information systems, and facility maintenance services.

The Company has two branches, the first in Riyadh, Kingdom of Saudi Arabia “Branch of Dr. Sulaiman Al Habib Medical Services Group Company” (“the Branch”) under commercial registration number 1010357146 dated 24 Muharram 1434H (corresponding to 8 December 2012). The objectives of the Branch include trading in wholesale and retail of cosmetics and maintenance of medical equipment. The second one in the Kingdom of Bahrain “Dr. Sulaiman Al-Habib Medical Services Group Holding Company - Foreign Branch” (“the Foreign Branch”) under commercial registration number 81609-1 dated 22 Rajab 1433H (corresponding to 12 June 2012).). The objectives of the Foreign Branch include activities of head offices or Management offices.

The Company capital number of shares is 350,000,000 and the share value is 10 Saudi riyals.

The interim condensed consolidated financial statements include the financial information of the branches mentioned above and subsidiaries mentioned in note 3.

2. Basis of preparation

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements that are endorsed by Saudi Organization for Chartered and Professional Accountants (collectively referred to as “IFRS as endorsed in Kingdom of Saudi Arabia”).

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should therefore be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2020.

These interim condensed consolidated financial statements are prepared on a historical cost basis. The interim condensed consolidated financial statements are presented in Saudi Riyals, which is the functional, and presentation currency of the Company and all values are rounded to the nearest one Riyal, except when otherwise indicated.

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements (continued)
30 September 2021**

3. Basis of consolidation

These interim condensed consolidated financial statements comprise the financial statements of the Company and its following subsidiaries (collectively referred to as "the Group"), domiciled in Kingdom of Saudi Arabia ("KSA") and United Arab Emirates ("UAE") as at 30 September 2021 & 31 December 2020:

	Country of incorporation and business	Activities	Ownership %	
			30	31
			September 2021	December 2020
Sehat Al Olaya Medical Complex Company	KSA	Hospital	100%	100%
Asharq Alawsat Pharmacies Company*	KSA	Pharmacy	100%	100%
Dr. Sulaiman Al Habib Hospital FZ – LLC	UAE	Hospital	100%	100%
Buraidah Al Takhassusi Hospital for Healthcare Company	KSA	Hospital	100%	100%
Al Rayan Hospital for Healthcare Company	KSA	Hospital	100%	100%
Home Healthcare Company	KSA	Home Healthcare services	100%	100%
Antab Al Riyadh for Operation and Maintenance Company**	KSA	Anciliary services	-	100%
Al Gharb Al Takhassusi Hospital for Healthcare Company	KSA	Hospital	100%	100%
Al Mokhtabarat Diagnostic Medical Company	KSA	Laboratory Services	100%	100%
Sehat Al Suwaidi Medical Company	KSA	Hospital	100%	100%
Hulool Al Sahaba for IT & Communication Company	KSA	IT Support Services	100%	100%
Al Rayan for Maintenance and Operation Company**	KSA	Anciliary services	-	100%
Al Afia Pharmacies for Medicines Company**	KSA	Pharmacy	-	100%
Intensive Care Company for Healthcare	KSA	Medical Services	100%	100%
Sehat Al Sharq Medical Limited Company	KSA	Hospital	50%	50%
Al Wosta Medical Limited Company	KSA	Hospital	50%	50%
Gharb Jeddah Hospital Company	KSA	Hospital	50%	50%
Shamal Al Riyadh for Healthcare Company	KSA	Hospital	100%	100%
Al Muhammadiyah Hospital for Healthcare Company	KSA	Hospital	100%	100%
Taswyat Management Company	KSA	Revenue cycle management	100%	100%
Al Marakez Al Awwalyah for Health Care Company	KSA	Medical Primary Healthcare centers	100%	100%
Rawabet Medical Company	KSA	Telemedicine services	100%	100%
Flow Medical Company	KSA	Medical equipments maintenance	100%	-
Sehat Al Kharj for Healthcare Company	KSA	Hospital	100%	-

*During 2020, the other partner (other party) has assigned his share to the benefit of the Company (which is 1%).

**During 2021, Al Afia Pharmacies for Medicines Company, Antab Al Riyadh for Operation and Maintenance Company and Al Rayan for Maintenance and Operation Company were transferred as a branch to Asharq Alawsat Pharmacies Company, Sehat Al Olaya Medical Complex Company and Al Rayan Hospital for Healthcare respectively. All legal requirements related to the transfer were completed. Transfer was done at net book value of the assets and liabilities.

3. Basis of consolidation (continued)

Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee);
- Exposure, or rights, to variable returns from its involvement with the investee;
- The ability to use its power over the investee to affect its returns.

Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement(s) with the other vote holders of the investee;
- Rights arising from other contractual arrangements;
- The Group's voting rights and potential voting rights.

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the interim condensed consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent of the Group and non-controlling interest, even if this results in the non-controlling interest having a deficit balance.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:

- Derecognizes the assets and liabilities of the subsidiary;
- Derecognizes the carrying amount of any non-controlling interest;
- Recognizes the fair value of the consideration received;
- Recognizes the fair value of any investment retained;
- Recognizes any surplus or deficit in profit or loss;
- Reclassifies the parent's share of components previously recognized in other comprehensive income to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities.

4. Summary of significant accounting policies

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in preparing the Group's annual consolidated financial statements for the year ended 31 December 2020.

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements (continued)
30 September 2021**

5. Segment Information

Operating segments is determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM"). The CODM uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments' results as it reflects the segments' performance for the period under evaluation. Revenue and segment profit is a consistent measure within the Group.

The identified key segments are Hospitals/Healthcare Facilities, Pharmacies and HMG Solutions / Others. The segment results for the period ended 30 September 2021 and the reconciliation of the segment measures to the respective statutory items included in the consolidated financial information are as follows:

For the period ended 30 September 2021 (Unaudited)	Hospitals/ Healthcare Facilities	Pharmacies	HMG Solutions / Others	Total
	<i>SR' millions</i>			
Saudi Arabia:				
Revenue	3,781	923	209	4,913
Gross profit	1,242	309	76	1,627
Outside Saudi Arabia:				
Revenue	323	43	3	369
Gross profit	48	9	3	60
Total				
Revenue	4,104	966	212	5,282
Gross profit	1,290	318	79	1,687
Unallocated income (expenses)				
Selling and marketing				(164)
General and administrative				(453)
Operating income				1,070
Share of income of associates				7
Finance costs				(29)
Other income				51
Income before zakat				1,099
Zakat				(100)
Income for the period				999
As at 30 September 2021 (Unaudited)				
Saudi Arabia:				
Total assets	7,196	293	2,235	9,724
Total liabilities	3,682	397	691	4,770
Outside Saudi Arabia				
Total assets	510	38	12	560
Total liabilities	116	11	3	130
Total				
Total assets	7,706	331	2,247	10,284
Total liabilities	3,798	408	694	4,900

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements (continued)
30 September 2021**

5. Segment Information (continued)

For the period ended 30 September 2020 (Unaudited)	Hospitals/ Healthcare Facilities	Pharmacies	HMG Solutions / Others	Total
<i>SR' millions</i>				
Saudi Arabia:				
Revenue	2,924	696	204	3,824
Gross profit	932	232	96	1,260
Outside Saudi Arabia:				
Revenue	332	11	3	346
Gross profit	54	2	3	59
Total				
Revenue	3,256	707	207	4,170
Gross profit	986	234	99	1,319
Unallocated income (expenses)				
Selling and marketing				(181)
General and administrative				(352)
Operating income				786
Share of income of associates				(2)
Finance costs				(38)
Other income				42
Income before zakat				788
Zakat				(72)
Income for the period				716
As at 31 December 2020 (audited)				
Saudi Arabia:				
Total assets	6,328	304	2,289	8,921
Total liabilities	3,168	326	782	4,276
Outside Saudi Arabia				
Total assets	536	15	9	560
Total liabilities	100	15	2	117
Total				
Total assets	6,864	319	2,298	9,481
Total liabilities	3,268	341	784	4,393

6. Property and equipment

	As at 30 September 2021 SR (Unaudited)	As at 31 December 2020 SR (Audited)
Property and equipment	6,059,483,622	5,365,719,651
Right-of-use assets	270,684,389	282,223,471
	6,330,168,011	5,647,943,122

7. Dividends

The Board of Directors, in their meetings during the period ended 30 September 2021 resolved to distribute interim dividends of SR 2.00 per share totaling to SR 700,000,000 (2020: SR 0.90 per share totalling to SR 315,000,000). This will be endorsed by the Company's upcoming general assembly.

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements (continued)
30 September 2021**

8. Long-term loans

	As at 30 September 2021 SR (Unaudited)	As at 31 December 2020 SR (Audited)
Current-portion of loans:		
Loans from local banks (i)	259,504,051	305,817,344
Loans from Ministry of Finance (ii)	25,505,344	24,203,407
	285,009,395	330,020,751
Non-current portion of loans:		
Loans from local banks (i)	1,890,282,412	1,628,013,057
Loans from Ministry of Finance (ii)	381,258,322	401,627,707
	2,271,540,734	2,029,640,764

i) Loans from local banks

The Group is financed through Islamic facilities in the form of long-term and short-term loans (Murabaha / Tawarruq) from local banks. These facilities are subject to commission rates based on Saudi Arabia Interbank Offered Rate "SIBOR" plus an agreed margin. The facilities are secured by corporate promissory notes.

ii) Loans from Ministry of Finance (MoF)

The Group's long-term financing includes MoF non-interest bearing loans to finance the capital expenditures related to the Company and its subsidiaries. The loan repayment instalments are settled on equal yearly instalments. Certain assets are pledged against the loans obtained from the MoF .

9. Earnings per share

Basic and diluted earnings per share ("EPS") is calculated by dividing the income for the period attributable to ordinary equity holders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per share is the same as the regular or basic earnings per share as the Group does not have any convertible securities or diluted instruments to exercise.

The following table reflects the income for the period attributable to equity holders of the parent and share data used in the basic and diluted EPS computations:

	For the three months period ended		For the nine month period ended	
	30 September 2021 SR	30 September 2020 SR	30 September 2021 SR	30 September 2020 SR
<i>Income for the period attributable to equity holders of the parent</i>	348,624,327	298,794,733	993,024,138	737,647,874
Weighted average number of ordinary shares	350,000,000	350,000,000	350,000,000	350,000,000
Basic and diluted earnings per share from income for the period attributable to equity holders of the parent	1.00	0.85	2.84	2.11

10. Fair values

Financial instruments comprise financial assets and financial liabilities. Financial assets consist of cash and cash equivalents and accounts receivable. Financial liabilities consist of long-term loans, accounts payable, advances from customers, amounts due to related parties, accrued expenses and other liabilities and zakat payable.

The fair value of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of financial instruments are not materially different from their carrying values at reporting date largely.

11. Significant event

The existence of novel coronavirus (COVID-19) was confirmed in early 2020 and has spread globally, including the Kingdom of Saudi Arabia, causing disruptions to many businesses and economic activities.

The extent and duration of such impacts remain uncertain and dependent on future developments that cannot be reliably predicted at this time, such as the transmission rate of the coronavirus and the extent and effectiveness of containment actions taken. Given the ongoing economic uncertainty, a reliable estimate of the impact cannot be made at the reporting date of these interim condensed consolidated financial statements. These developments are not expected to have a material impact on the Group's future financial results, cash flows and financial condition.

12. Subsequent events

In the opinion of management, no significant events have occurred subsequent to 30 September 2021 that would have a material impact on financial position or financial performance of the Group.

13. Approval of the interim condensed consolidated financial statements

These interim condensed consolidated financial statements were approved for issuance by the Board of Directors on 17 Rabi Al Awwal 1443H (corresponding to 23 October 2021).

14. Comparative information

Certain comparative information has been reclassified to align with current period presentation for the period ended 30 September 2021.